ASX · ICR.AX
Intelicare Holdings Limited
A$0.02A$0.00 (0.0%)
Intelicare Holdings Limited’s quoted price sits in the lower half of its reported 52-week range, 37.5% below the high.
Loading market information…
ASX · CAN.AX · AUD
Stock price, earnings
Quote as of Oct 30, 2026, 04:15 AM UTC. Cached market data; not a live quote.
One-year closing-price history · AUD. Historical prices are not a forecast.
Cann Group Limited’s quoted price sits in the lower half of its reported 52-week range, 61.54% below the high.
52-week range
Go beyond this overview with deeper company research in PortfolioX. Explore more in the app
BEHIND THE RESULTS
Cann Group Limited’s next earnings report is currently expected on Feb 26, 2027. The reporting date and estimates may change.
Upcoming dates and analyst estimates may change. Fiscal quarters follow Cann Group Limited’s reporting calendar.
THE COMPANY BEHIND THE TICKER
Cann Group Limited, established in Port Melbourne, Australia, in 2014, specializes in the comprehensive lifecycle of medicinal cannabis. This includes genetic development, cultivation, manufacturing, clinical assessment, and the distribution of therapeutic cannabis products. The company supplies these products for use within Australia and also exports them to international markets, operating under specific licenses that permit research and the cultivation of cannabis for human medicinal and scientific purposes.
Latest available per-share figures in AUD. The payout ratio compares dividends with earnings.
About this data · PortfolioX market data, also available in the mobile app. Prices are displayed in the listing currency; dividend amounts use the currency shown in that section. Data availability and update times vary.
Page generated Oct 30, 2026, 05:10 AM UTC. Quotes retain their own timestamp above. Missing values appear as a dash. This page is for information only, not personalized investment advice.
HOW THE BUSINESS IS PERFORMING
Statement amounts use the company’s reporting currency and are not converted to the stock’s listing currency. K = thousand, M = million, B = billion, T = trillion. Cash-flow figures are matched by fiscal year; missing figures appear as a dash.
PUT THE NUMBERS IN CONTEXT
Current metrics alongside available historical medians. A lower multiple or higher margin alone does not establish whether a stock is a good investment.
KEEP COMPARING
A$0.02A$0.00 (0.0%)
Intelicare Holdings Limited’s quoted price sits in the lower half of its reported 52-week range, 37.5% below the high.
A$0.01A$0.00 (0.0%)
ECS Botanics Holdings Ltd’s quoted price sits in the lower half of its reported 52-week range, 37.5% below the high.
A$0.03A$0.00 (0.0%)
InhaleRx Limited’s quoted price sits in the lower half of its reported 52-week range, 41.67% below the high.
A$0.08-A$0.00 (-5.06%)
Vectus Biosystems Limited’s quoted price sits in the lower half of its reported 52-week range, 83.52% below the high.
A$0.04-A$0.00 (-5.41%)
Invion Limited’s quoted price sits in the lower half of its reported 52-week range, 68.18% below the high.
A$0.01+A$0.00 (+7.69%)
Bio-Gene Technology Limited’s quoted price sits in the lower half of its reported 52-week range, 71.43% below the high.
A$0.00-A$0.00 (-25.0%)
HITIQ Limited’s quoted price sits in the lower half of its reported 52-week range, 92.5% below the high.
A$0.00+A$0.00 (0.0%)
Percheron Therapeutics Limited’s quoted price sits in the lower half of its reported 52-week range, 70.0% below the high.
